



29 July 2015

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

Dear Sir/Madam

CANNABIS LICENCE

Medlab Clinical Limited (ASX: MDC – “Medlab” or “Company”) is pleased to advise that the New South Wales government has granted a research licence to Medlab for the use of medical cannabis, making Medlab one of the first commercial corporates in Australia to undertake cannabis work.

Medlab operates a certified biologics laboratory facility in Sydney and its research on cannabis will be for therapeutic purposes, including development of an alternative method of administration of cannabis, for example buccal* delivery.

Medlab’s research will broadly encompass pain management as well as other medical conditions for varying age groups.

Medlab intends to use its patented small particle delivery platform, NanoCelle for therapeutic cannabis applications. Using the NanoCelle™ platform, Medlab believes smaller doses of a compound (e.g. Cannabis) can be used in patient care, resulting in less risk and/or complication to the patient. Further the NanoCelle™ platform decreases the possibility of social misuse of the product. As the NanoCelle™ platform is developed, Medlab expects a speedier research timeframe, and hopefully a faster product release to market.

Medlab would specifically like to thank the various Government agencies involved in the registration process.

Yours Sincerely



Sean Hall
Managing Director

For media enquiries contact:
Marcha Van Den Heuvel
Hill – Knowlton Strategies
+ 61 2 9286 1226
marcha.vandenheuvel@hkstrategies.com

* Buccal administration involves placement of the drug between the gums and the cheek. These medications can come in the form of tablets, films, or sprays.
(Source <http://www.healthline.com/health/sublingual-and-buccal-medication-administration#Definition1>)